New asthma educational website launched
WASHINGTON — A division of drug maker Teva Pharmaceutical Industries is partnering with an advocacy group focused on asthma in the launch of a new educational website about the condition.
The Asthma and Allergy Foundation of America and Teva Respiratory announced the launch of Get Smart About Asthma, which aims to increase understanding of how inflammation in the airways contributes to the disease’s persistence and severity, as well as providing other educational materials.
"Many of the 25 million Americans who suffer from asthma may know the basics about their condition, but GetSmartAboutAsthma.com will expand their knowledge even more," Georgia Pediatric Pulmonology Associates pediatric pulmonologist LeRoy Graham said. "Asthma is a life-long condition that, if not managed properly, also can be life-threatening."
No comments found
Perrigo, Ther-Rx announce availability of Gynazole-1
ST. LOUIS — Perrigo and a subsidiary of K-V Pharmaceutical Co. have launched a new drug for yeast infections in women, the two companies said.
Perrigo and Ther-Rx Corp. announced the availability of Gynazole-1 (butoconazole nitrate vaginal cream) in the 2% strength for treating yeast infections in nonpregnant women.
Ther-Rx has a partnership with Perrigo to manufacture the drug.
"We are pleased to be able to once again offer Gynazole-1 to prescribing healthcare providers and to patients in need of therapy," K-V CEO and Ther-Rx president Greg Divis said. "The availability of Gynazole-1 represents a positive step forward for the company as we continue to provide quality, patient-friendly products to support the health of women across the stages of their lives."
It’s official: Watson changes name to Actavis
PARSIPPANY, N.J. — Watson Pharmaceuticals has formally changed its name to Actavis and changed its New York Stock Exchange ticker symbol to ACT, the company said Thursday.
The generic drug maker, now the world’s third largest, announced its plan to change the name last year after it acquired Actavis. The combined company expects combined 2012 sales to exceed $8 billion.
"Today marks an historic day for Actavis and a milestone in our evolution into a global pharmaceutical leader," Actavis president and CEO Paul Bisaro said. "While we have been operating as one company since last year, today we unite all of our 17,000 employees under a single name, trademarked and protected around the world."
The company has started a multi-year rebranding campaign in which it will change its website, factories, operations and commercial presence around the world and plans to ring the closing bell Thursday at the New York Stock Exchange.
No comments found